(Press-News.org) LA JOLLA, CA ---- For many migraine sufferers, bright lights are a surefire way to exacerbate their headaches. And for some night-shift workers, just a stroll through a brightly lit parking lot during the morning commute home can be enough to throw off their body's daily rhythms and make daytime sleep nearly impossible. But a new molecule that selectively blocks specialized light-sensitive receptors in the eyes could help both these groups of people, without affecting normal vision.
"It took almost ten years to find and test a molecule that fit all the properties and acted in vivo as we wanted," says senior study author Satchidananda Panda , an associate professor in Salk's Regulatory Biology Laboratory .
Scientists have known for nearly a century that humans and animals can sense light even when they can't see. Before they've opened their eyes, and even before cells that allow vision have matured, newborn mice still scurry away from bright lights, and set their sleep-wake cycles based on the patterns of light and dark throughout the day. The same is true of many blind people-though they can't see what's in front of them, their bodies still follow daily circadian rhythms, and the pupils of their eyes constrict in response to light.
More than ten years ago, Panda's lab group discovered that melanopsin, a receptor found in neurons connecting the eyes and brain, is responsible for sensing light independently of normal vision. Since then, researchers have determined that the receptor is vital for maintaining sleep cycles and other circadian rhythms in those with healthy vision, constricting the pupil of the eye in bright light, and potentially exacerbating the light-sensitivity associated with migraine headaches. While melanopsin senses light for these non-vision purposes in the body, closely related receptors-rhodopsin and cone opsins-provide vision-forming information to the brain.
Panda figured that if he could find a compound that blocked melanopsin, but not rhodopsin or cone opsins, it could pave the way toward treating migraines or circadian rhythm imbalances. Scientists already know of one class of compounds, retinoids, which interact with opsins, but they're non-specific and so bind to melanopsin, rhodopsin, cone opsins, and a whole handful of other receptors in the body, causing widespread side effects. Panda wanted something more specific. So for ten years, his lab group, in collaboration with scientists at the pharmaceutical company Lundbeck, has attempted to find chemical compounds that specifically shut off melanopsin in animals.
In their latest search, Panda and his collaborators turned to the Lundbeck library of diverse compounds. In hundreds of 384-well plates, a team led by Ken Jones at Lundbeck tested whether each chemical from the library turned off melanopsin by measuring the calcium levels after the plate was exposed to light. When melanopsin is functioning, calcium levels increase after light exposure indicating that light has been sensed and a signal is being generated. Several compounds from the chemical library stopped this calcium increase from happening, suggesting that they were blocking the function of melanopsin.
None of these compounds looked like retinoids, so it was an exciting breakthrough, Panda says. The chemicals, dubbed opsinamides, also showed no interaction with rhodopsin or other opsins. "We wanted to make sure they were specific to melanopsin," says Panda. To find out whether the opsinamides would have a physiological response in addition to binding to melanopsin in bench experiments, Megumi Hatori and Ludovic Mure from Panda's Salk lab group next looked at whether the drug affected the pupillary constriction in mice. Normally, in extremely bright light, the pupil of the eye shrinks to its smallest size. But when the mice were treated with one of the opsinamides, their pupils didn't shrink as usual. Most importantly, the drug had no detectable effect in mice lacking melanopsin, further showing its specificity for melanopsin. Finally, newborn mice treated with the compound no longer avoided bright lights. The results, Panda says, show that the drug is stopping melanopsin from signaling the brain when the eyes are exposed to bright light.
"So far, everything known about melanopsin has been discovered using knock-out mice that completely lack the receptor," says Panda. "So this offers a new way to study the protein." Kenneth Jones, the former project head at Lundbeck, notes that "the two compounds require further optimization in anticipation of clinical testing but are extraordinarily useful for research purposes and as leads in the discovery process." Co-author Jeffrey Sprouse has co-founded a start-up company, Cyanaptic, to do just that.
Once more effective compounds are developed, Panda expects that they could eventually have utility in a variety of clinical settings. "There are many people who would like to work when they have migraine pain exacerbated by light," he says. "If these drugs could stop the light-sensitivity associated with the headaches, it would enable them to be much more productive."
Moreover, Panda says, the drugs could help shift-workers set their sleep schedules without exposure to sunlight interfering with their circadian rhythms. His lab group doesn't yet have results on how the drugs affect circadian rhythms, but based on the known mechanisms of melanopsin, Panda says that it is likely the new opsinamides alter sleep.
INFORMATION:
Other researchers on the study were Megumi Hatori, Ludovic S. Mure and Quansheng Zhu of the Salk Institute for Biological Studies; Kenneth A. Jones, Roman Artymyshyn, Sang-Phyo Hong, Mohammad Marzabadi, Huailing Zhong and Jeffrey Sprouse of Lundbeck Research USA Inc.; Jayne R. Bramley, Patricia J. Sollars and Gary E. Pickard of the University of Nebraska; and Andrew T.E. Hartwick of The Ohio State University.
The work was supported by grants from the Hearst Foundations, the National Institutes of Health, the Japan Society for the Promotion of Science, and the Catharina Foundation. Six of the authors were employees of Lundbeck Research USA during the period of time that the experimental work was conducted.
About the Salk Institute for Biological Studies:
The Salk Institute for Biological Studies is one of the world's preeminent basic research institutions, where internationally renowned faculty probe fundamental life science questions in a unique, collaborative, and creative environment. Focused both on discovery and on mentoring future generations of researchers, Salk scientists make groundbreaking contributions to our understanding of cancer, aging, Alzheimer's, diabetes and infectious diseases by studying neuroscience, genetics, cell and plant biology, and related disciplines.
Faculty achievements have been recognized with numerous honors, including Nobel Prizes and memberships in the National Academy of Sciences. Founded in 1960 by polio vaccine pioneer Jonas Salk, M.D., the Institute is an independent nonprofit organization and architectural landmark.
Drug blocks light sensors in eye that may trigger migraine attacks
New compound by Salk scientists offers a way to treat migraine and potentially other disorders of the central nervous system
2013-08-27
ELSE PRESS RELEASES FROM THIS DATE:
JCI early table of contents for Aug. 27, 2013
2013-08-27
Hearing loss associated with a lack of cell-cell junctions
Sound waves are filtered through the outer ear to the cochlea, where hair cells convert the sound into the electric impulses that travel through the auditory nerve to the brain. Cochlear hair cells are extremely sensitive to stress and loss of these cells is a common cause of deafness. The formation of tight junctions between cells allows epithelia to form barriers to prevent fluid and other molecules from moving freely throughout the body. In this issue of the Journal of Clinical Investigation, Saima Riazuddin ...
Hearing loss associated with a lack of cell-cell junctions
2013-08-27
Sound waves are filtered through the outer ear to the cochlea, where hair cells convert the sound into the electric impulses that travel through the auditory nerve to the brain. Cochlear hair cells are extremely sensitive to stress and loss of these cells is a common cause of deafness. The formation of tight junctions between cells allows epithelia to form barriers to prevent fluid and other molecules from moving freely throughout the body. In this issue of the Journal of Clinical Investigation, Saima Riazuddin and colleagues at the Cincinnati Children's Hospital, identify ...
Cancerous cells from donor kidney linked to recipient skin cancer
2013-08-27
Patients that receive kidney transplants have an increased risk of an invasive form of skin cancer. It is unclear if donor tissue contributes to cancer formation. In this issue of the Journal of Clinical Investigation, Philippe Ratajczak and colleagues at INSERM demonstrate that donor tissue can lead to caner formation in transplant recipients. They examined tumor cells and transplant tissues from a small sample of kidney transplant patients that had subsequently developed skin squamous cell carcinoma (SCC). In one patient they identified the presence of skin tumor cells ...
A strategy for combating drug-resistant cancers
2013-08-27
Many cancer therapies function by activating proteins like Caspase-3 (CASP3) that promote cell death. Several forms of cancer develop resistance to these drugs by down regulating CASP3 through an unknown mechanism. In the absence of CASP3, tumor cells produce another cell death promoting protein CASP7, but it is rendered inactive by the X-linked inhibitor of apoptosis protein (XIAP). In this issue of the Journal of Clinical Investigation, Po-Huang Liang and colleagues at Academia Sinica identify a compound (I-Lys) that disrupts the interaction between CASP7 and XIAP. Release ...
Protease inhibitor resistance involves multiple stages of the HIV-1 life cycle
2013-08-27
HIV-1 protease inhibitors are very effective antiviral drugs. These drugs target HIV-1 proteases, which are required for viral replication. Despite the success of protease inhibitors for suppressing HIV-1, some patients do not respond to protease inhibitor therapy. For most patients, the lack of response is not due to mutation of the HIV-1 protease. In this issue of the Journal of Clinical Investigation, Robert Silcano and colleagues at Johns Hopkins University identify the effects of protease inhibitors on different stages of viral replication. The authors found that protease ...
Origin of a hereditary east Texas bleeding disorder
2013-08-27
A severe hereditary bleeding disorder was described in a large family from east Texas in 2001. The affected family members routinely had bruising, nosebleeds, massive blood loss following injury or surgery, and often required blood transfusions. Routine tests for functional components of the blood coagulation pathway did not reveal any obvious defects. Genomic sequencing revealed a mutation in the gene encoding coagulation factor 5 (FV), but it was not considered to contribute to disease, since clotting assays were normal. In this issue of the Journal of Clinical Investigation, ...
Scientists prevent preterm birth caused by gene-environment interactions
2013-08-27
CINCINNATI – New research in the Journal of Clinical Investigation provides evidence that gene-environment interactions are a major contributor to preterm birth and that using a combinatory treatment strategy can prevent preterm delivery in a mouse model.
In findings posted online Aug. 27, scientists from Cincinnati Children's Hospital Medical Center say their study provides important new insights into a major global health problem – one that remains stubbornly persistent in the United States. Preterm birth causes more than 1 million deaths a year and can leave premature ...
Study finds tumor suppressor may actually fuel aggressive leukemia
2013-08-27
CINCINNATI – New research in the Journal of Clinical Investigation suggests that blocking a protein normally credited with suppressing leukemia may be a promising therapeutic strategy for an aggressive form of the disease called acute myeloid leukemia (AML).
Researchers from Cincinnati Children's Hospital Medical Center report their results in a study posted online Aug. 27 by the journal.
The protein scientists targeted is a transcription factor known as RUNX1, which also plays an important role in helping regulate the normal development of blood cells. The researchers ...
Study identifies molecular process behind form of non-syndromic deafness
2013-08-27
CINCINNATI – Researchers identify an underlying molecular process that causes a genetic form of non-syndromic deafness in a new study that also suggests affected families may be at risk of damage to other organs.
A multi-national research team led by scientists at Cincinnati Children's Hospital Medical Center report their findings in a study posted online Aug. 27 by the Journal of Clinical Investigation. The research opens the door to finding possible treatments for the condition (called DFNB49 non-syndromic hearing loss) and points to possible cellular damage in other ...
Personalized AF management needed to close mortality gap
2013-08-27
Amsterdam, The Netherlands – Tuesday 27 August 2013: Personalised management is the only way to close the mortality gap for patients with atrial fibrillation (AF), according to an ESC consensus paper presented at ESC Congress 2013 by Professor Paulus Kirchhof (UK).
The Atrial Fibrillation competence NETwork (AFNET) and European Heart Rhythm Association (EHRA) consensus paper is published online in the European Journal of Pacing, Arrhythmias, and Cardiac Electrophysiology (EP-Europace)1 and presented during the ESC Congress session on personalised cardiology.
Professor ...
LAST 30 PRESS RELEASES:
Call for papers: 14th Asia-Pacific Conference on Transportation and the Environment (APTE 2025)
A novel disturbance rejection optimal guidance method for enhancing precision landing performance of reusable rockets
New scan method unveils lung function secrets
Searching for hidden medieval stories from the island of the Sagas
Breakthrough study reveals bumetanide treatment restores early social communication in fragile X syndrome mouse model
Neuroscience leader reveals oxytocin's crucial role beyond the 'love hormone' label
Twelve questions to ask your doctor for better brain health in the new year
Microelectronics Science Research Centers to lead charge on next-generation designs and prototypes
Study identifies genetic cause for yellow nail syndrome
New drug to prevent migraine may start working right away
Good news for people with MS: COVID-19 infection not tied to worsening symptoms
Department of Energy announces $179 million for Microelectronics Science Research Centers
Human-related activities continue to threaten global climate and productivity
Public shows greater acceptance of RSV vaccine as vaccine hesitancy appears to have plateaued
Unraveling the power and influence of language
Gene editing tool reduces Alzheimer’s plaque precursor in mice
TNF inhibitors prevent complications in kids with Crohn's disease, recommended as first-line therapies
Twisted Edison: Bright, elliptically polarized incandescent light
Structural cell protein also directly regulates gene transcription
Breaking boundaries: Researchers isolate quantum coherence in classical light systems
Brain map clarifies neuronal connectivity behind motor function
Researchers find compromised indoor air in homes following Marshall Fire
Months after Colorado's Marshall Fire, residents of surviving homes reported health symptoms, poor air quality
Identification of chemical constituents and blood-absorbed components of Shenqi Fuzheng extract based on UPLC-triple-TOF/MS technology
'Glass fences' hinder Japanese female faculty in international research, study finds
Vector winds forecast by numerical weather prediction models still in need of optimization
New research identifies key cellular mechanism driving Alzheimer’s disease
Trends in buprenorphine dispensing among adolescents and young adults in the US
Emergency department physicians vary widely in their likelihood of hospitalizing a patient, even within the same facility
Firearm and motor vehicle pediatric deaths— intersections of age, sex, race, and ethnicity
[Press-News.org] Drug blocks light sensors in eye that may trigger migraine attacksNew compound by Salk scientists offers a way to treat migraine and potentially other disorders of the central nervous system